124 filings
Page 2 of 7
10-Q
2023 Q3
ACXP
Acurx Pharmaceuticals Inc
Quarterly report
13 Nov 23
12:00am
8-K
ACXP
Acurx Pharmaceuticals Inc
3 Nov 23
Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection
4:05pm
8-K
ACXP
Acurx Pharmaceuticals Inc
2 Oct 23
Other Events
4:41pm
8-K
ACXP
Acurx Pharmaceuticals Inc
14 Aug 23
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2023 Results and Provides Business Update
7:10am
10-Q
2023 Q2
ACXP
Acurx Pharmaceuticals Inc
Quarterly report
11 Aug 23
4:05pm
424B3
ACXP
Acurx Pharmaceuticals Inc
13 Jul 23
Prospectus supplement
4:32pm
EFFECT
ACXP
Acurx Pharmaceuticals Inc
11 Jul 23
Notice of effectiveness
12:15am
CORRESP
ACXP
Acurx Pharmaceuticals Inc
6 Jul 23
Correspondence with SEC
12:00am
UPLOAD
ACXP
Acurx Pharmaceuticals Inc
5 Jul 23
Letter from SEC
12:00am
S-1
ACXP
Acurx Pharmaceuticals Inc
IPO registration
29 Jun 23
4:07pm
8-K
ACXP
Acurx Pharmaceuticals Inc
20 Jun 23
Amendments to Articles of Incorporation or Bylaws
4:44pm
4
ACXP
Acurx Pharmaceuticals Inc
16 Jun 23
Acurx Pharmaceuticals / James J. Donohue ownership change
5:46pm
4
Thomas L Harrison
16 Jun 23
Acurx Pharmaceuticals / THOMAS L HARRISON ownership change
5:46pm
4
ACXP
Acurx Pharmaceuticals Inc
16 Jun 23
Acurx Pharmaceuticals / JACK H DEAN ownership change
5:45pm
4
ACXP
Acurx Pharmaceuticals Inc
16 Jun 23
Acurx Pharmaceuticals / Carl Sailer ownership change
5:45pm
4
ACXP
Acurx Pharmaceuticals Inc
16 Jun 23
Acurx Pharmaceuticals / Joseph C Scodari ownership change
5:45pm
424B3
ACXP
Acurx Pharmaceuticals Inc
18 May 23
Prospectus supplement
4:15pm
424B5
ACXP
Acurx Pharmaceuticals Inc
17 May 23
Prospectus supplement for primary offering
4:25pm
8-K
ACXP
Acurx Pharmaceuticals Inc
17 May 23
Acurx Pharmaceuticals, Inc. Announces Pricing of $4.0 Million Registered Direct Offering
4:19pm
10-Q
2023 Q1
ACXP
Acurx Pharmaceuticals Inc
Quarterly report
12 May 23
7:00am